Clinical Trials Logo

Filter by:
NCT ID: NCT03231449 Active, not recruiting - Stroke Clinical Trials

A Survey of Hospitalizations in Cardiology Units in Sub-Saharan Africa

FEVRIER
Start date: February 1, 2017
Phase: N/A
Study type: Observational

FEVRIER study is an observatory of hospitalizations in cardiology units in sub-Saharan Africa.

NCT ID: NCT03214692 Enrolling by invitation - Clinical trials for End-Stage Renal Disease

Gum Arabic as Antioxidant and Anti-inflammatory in Hemodialysis Patients

GA&CRF
Start date: July 2017
Phase: N/A
Study type: Interventional

Oxidative processes increased in patients with renal failure and especially patients with end stage renal failure on dialysis. Oxidative stress plays a role in renal damage and also on cardiovascular disease, atherosclerosis, which can accelerate renal damage. Gum Arabic is claimed to have antioxidant effect and this will decrease the harmful effect of the free radical on patient on hemodialysis. In this study investigators are aiming to see the effect of Gum Arabic on Oxidative Stress and inflammatory markers in patients on regular hemodialysis.

NCT ID: NCT03138044 Recruiting - Clinical trials for Hepatocellular Carcinoma

Combined Ipsilateral Liver Lobe Devascularization and Alcohol Treatment of the Large Hepatocellular Carcinoma

Start date: May 1, 2017
Phase: N/A
Study type: Interventional

Assessment of the long-term outcome of combined ipsilateral liver lobe devascularization (ILAD) and alcohol injection of the large hepatocellular carcinoma (HCC): single center non-randomized trial.

NCT ID: NCT03138031 Recruiting - Clinical trials for Hepatocellular Carcinoma Non-resectable

Percutaneous Ethanol Alcohol Injection for the Large and Unresectable Hepatocellular Carcinoma

Start date: May 1, 2017
Phase: N/A
Study type: Interventional

Assessment of the long-term outcome of percutaneous ethanol alcohol injection (PEI) for the large and unresectable hepatocellular carcinoma: single center non-randomized trial.

NCT ID: NCT03129685 Recruiting - Clinical trials for Hepatocellular Carcinoma

Ipsilateral Liver Lobe Devascularization of the Large Hepatocellular Carcinoma

NRU
Start date: April 2017
Phase: N/A
Study type: Interventional

Assessment of short-term outcomes of ipsilateral lobe arterial devascularization of the large hepatocellular carcinoma: single center non-randomized trial.

NCT ID: NCT03129646 Not yet recruiting - Clinical trials for Visceral Leishmaniasis

Miltefosine/Paromomycin Phase III Trial for Treatment of Primary Visceral Leishmaniasis (VL) Patients in Eastern Africa

Start date: August 1, 2017
Phase: Phase 3
Study type: Interventional

This is an open label, Phase III, randomized, controlled, parallel arm multicentre non-inferiority clinical trial to compare the efficacy and safety of two combination regimens of Miltefosine and Paromomycin with the standard SSG-PM for the treatment of primary adult and children VL patients in Eastern Africa.

NCT ID: NCT03112551 Enrolling by invitation - Pre-Eclampsia Clinical Trials

Safety and Efficacy of Twelve Hours Duration of MgSO4 in the Treatment of Eclampsia in Low Resource Setting in Sudan

Start date: September 1, 2017
Phase: N/A
Study type: Interventional

the investigators assume that magnesium sulphate for treating eclampsia can be safely reduced from 24 hours to shorter duration of therapeutic anticonvulsant effect for 12 hours. Short duration of drug exposure is suitable for low resource setting where there is little tools or busy staff for monitoring drug toxicity.

NCT ID: NCT03086226 Recruiting - Mycetoma Clinical Trials

Proof-of-Concept Superiority Trial of Fosravuconazole Versus Itraconazole for Eumycetoma in Sudan

Start date: April 30, 2017
Phase: Phase 2
Study type: Interventional

This study is a single-center, comparative, randomized, double-blind, parallel-group, active-controlled, clinical superiority trial of Fosravuconazole versus Itraconazole combined with surgery in subjects with eumycetoma in Sudan. There will be three arms in this study: The first arm will be Fosravuconazole 300 mg weekly, the second arm will have Fosravuconazole 200 mg weekly and the control arm is the standard treatment using itraconazole 400mg daily. At 3 months time-point, interim analysis will be done and one of the study arms will be dropped according to the drop-the-loser design, based on efficacy or toxicity.

NCT ID: NCT02894008 Recruiting - Clinical trials for Leishmaniasis, Cutaneous

A Study of a New Leishmania Vaccine Candidate ChAd63-KH

Leish2a
Start date: November 2016
Phase: Phase 2
Study type: Interventional

This is a study to assess the safety of a new candidate Leishmania vaccine ChAd63-KH in patients with persistent post kala azar dermal leishmaniasis (PKDL). This is a Phase II trial in patients with PKDL, to assess the safety and compare the humoral and cellular immune responses generated by the candidate vaccine in patients, and observe any clinical changes in the disease over a 42 day period following vaccination. Study design: Eight adult volunteers will receive 1x10(10)vp and the subsequent eight volunteers will receive 7.5 x10(10)vp. Adolescents will be vaccinated with either 1x10(10)vp or 7.5 x10(10)vp, to be determined by evaluation of all available data after DSMB & CTSC review.

NCT ID: NCT02804581 Recruiting - Clinical trials for Rheumatoid Arthritis

Gum Arabic as Immunomodulator In Rheumatoid Arthritis Patients

Start date: June 2016
Phase: Phase 2
Study type: Interventional

Gum Arabic (GA) rich dietary fiber it is a water-soluble dietary fiber derived from the dried gummy exudates of the stems and branches of Acacia senegal, GA found to have strong immuno modulator in vitro where it increased IL10 production showing strong anti-inflammatory effects (19). The aim of this study is to determine the role of gum Arabic in immunomodulation among patients with rheumatoid arthritis.